AKTS
Aktis Oncology, Inc.
$19.63
+0.67%
2026-02-26
About Aktis Oncology, Inc.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Key Fundamentals
Forward P/E
-10.21
EPS (TTM)
$-1.21
ROE
-29.4%
Revenue Growth (YoY)
100.4%
Profit Margin
0.0%
Debt/Equity
6.17
Market Cap
$1.02B
Avg Volume (10D)
214K
Recent Breakout Signals
No recent breakout signals detected for AKTS.
Recent Price Range (60 Days)
60D High
$29.16
60D Low
$16.80
Avg Volume
367K
Latest Close
$19.63
Get breakout alerts for AKTS
Sign up for Breakout Scanner to receive daily notifications when AKTS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Aktis Oncology, Inc. (AKTS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors AKTS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. AKTS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.